Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donanemab and RG6289 in Autosomal-Dominant Alzheimer's Disease
NCT06996730Phase 3Recruiting
- Sponsor
- Banner Health
- Start
- Jul 2026
- Primary completion
- Jun 2030
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of donanemab and nivegacetor in Alzheimer's disease (AD) (6 arms), sponsored by Banner Health. Primary endpoints: Change in amyloid load as measured by centiloid (CL) [F18]Florbetapir-PET at 18 months and Maintenance of Low Levels of Brain Amyloid as Measured by centiloid (Cl) [F18]Florbetapir-PET up to 18 months. Started Jul 2026; status: recruiting.
02
Drugs
donanemabnivegacetor
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06996730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06996730.